Ajanta Pharma logo

Ajanta Pharma financials and balance sheet

NSE: AJANTPHARMBSE: 532331Pharmaceuticals & BiotechnologyMid Cap

Last close ₹3,283.90up ₹13.30 (0.41%)BSE ₹3,281.15

Share price at the NSE close on 23 Oct 2026. Previous close ₹3,270.60.

52-week range of traded prices to 23 Oct 2026
₹2,382.00Low, 28 Oct 2025₹3,796.00High, 18 Aug 2026
Market cap
₹41,035 Cr236th largest listed
P/E
36.2
P/B
9.1
Dividend yield
1.83%
ROE
27.3%
ROCE
27.2%
Debt to equity
0.05
Volume, NSE
1,54,84762.5% delivered

10 years at a glance

Consolidated: the company and its subsidiaries together. ₹ crore, years to March.Ajanta Pharma annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
Peak revenue ₹5,453 Cr, year to Mar 2026

Operating and net margin, per cent

  • Operating margin
  • Net margin

From Apr 2019 leases sit on the balance sheet: rent is charged as depreciation and interest instead, so operating profit and total assets step up with nothing about the business having changed. Borrowings here leave lease liabilities out. Lease payments were 1.5% of operating profit in the first full year.

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue5,453
  2. Materials and goods−1,184
  3. Employee costs−1,291
  4. Other expenses−1,583
  5. Operating profit1,395
  6. Depreciation−173
  7. Other income+172
  8. One-off items0.0
  9. Finance costs−16
  10. Profit before tax1,378
  11. Tax−322
  12. Net profit1,056

What the company owns

  • Plant, investments and other assets₹2,698 Cr
  • Receivables₹1,854 Cr
  • Inventory₹939 Cr
  • Current investments₹560 Cr
  • Cash and bank₹105 Cr

What pays for it: net worth and liabilities

  • Net worth₹4,527 Cr
  • Other liabilities₹871 Cr
  • Owed to suppliers₹544 Cr
  • Borrowings₹212 Cr

Profit and loss

Consolidated, ₹ crore, years to March.Ajanta Pharma quarterly results

₹ croreMar 2017Mar 2018Mar 2019Filed 2 MayMar 2020Filed 21 MayMar 2021Filed 3 MayMar 2022Filed 11 MayMar 2023Filed 8 MayMar 2024Filed 3 MayMar 2025Filed 12 JunMar 2026Filed 5 May
Revenue from operations2,0022,1312,0552,5882,8903,3413,7434,2094,6485,453
1,3131,4721,4891,9051,8912,4122,9593,0373,3894,058
Materials and goods bought4154063836566458321,0501,0671,0711,184
Employee costs2953764314865486467859001,0901,291
Other expenses6036906757636989341,1241,0701,2281,583
Operating profit before depreciation6896585666839999297831,1721,2601,395
Operating margin34.4%30.9%27.6%26.4%34.6%27.8%20.9%27.8%27.1%25.6%
Materials, % of revenue20.7%19.1%18.7%25.3%22.3%24.9%28.1%25.3%23.0%21.7%
Employee costs, % of revenue14.8%17.7%21.0%18.8%19.0%19.3%21.0%21.4%23.4%23.7%
Other expenses, % of revenue30.1%32.4%32.8%29.5%24.1%27.9%30.0%25.4%26.4%29.0%
Depreciation and amortisation61607296116125131135144173
Operating profit after depreciation6285994945888828046521,0371,1151,222
Other income2424219226116998595172
Finance costs30112810672116
Profit before one-off items and tax6486235146689009097451,1141,1891,378
One-off items000−4000000
Profit before tax6486235146649009097451,1141,1891,378
141154127196246197157298269322
5074693874686547135888169201,056
Other comprehensive income––−36−6−8151229
Total comprehensive income––3844736477056038179221,085
Net margin25.3%22.0%18.8%18.1%22.6%21.3%15.7%19.4%19.8%19.4%

Balance sheet

Consolidated, ₹ crore, at 31 March.

₹ croreMar 2019Filed 2 MayMar 2020Filed 21 MayMar 2021Filed 3 MayMar 2022Filed 11 MayMar 2023Filed 8 MayMar 2024Filed 3 MayMar 2025Filed 12 JunMar 2026Filed 5 May
2,2452,5992,9963,2643,3883,5673,7904,527
Share capital1818171725252525
Reserves2,2282,5812,9783,2473,3633,5423,7654,502
344422113212
3786066496471,1398959961,416
73114134144152175229212
Liabilities going with businesses held for sale–––––1––
2,6963,3193,7794,0564,6794,6385,0156,155
1,5151,6771,7511,7911,8451,9072,1722,419
1,1811,6422,0282,2642,8252,7222,8303,735
Net debt−131−229−384−332−840−459−612−453
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Consolidated, ₹ crore, years to March.

₹ croreMar 2021Filed 3 MayMar 2022Filed 11 MayMar 2023Filed 8 MayMar 2024Filed 3 MayMar 2025Filed 12 JunMar 2026Filed 5 May
5765627927851,157529
8078019431,0971,480888
−209−20067−100179−653
Receivables31−270−11−17980−591
Inventories−271−26−22−12−75−31
Payables11−489741−891
Other working capital20143351181−122
Tax paid−230−239−151−312−323−359
Capital spending172149174152318365
Free cash flow405413617633839164
−282−74−56065−377−429
−318−460−108−1,051−733−168
Dividends paid838290642349350
Shares bought back13535413893530
Shares issued000000
Net change in cash−2428124−20147−68
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020.

Per share

Consolidated, ₹ per share, years to March.Ajanta Pharma dividend history

₹ per shareMar 2017Mar 2018Mar 2019Filed 2 MayMar 2020Filed 21 MayMar 2021Filed 3 MayMar 2022Filed 11 MayMar 2023Filed 8 MayMar 2024Filed 3 MayMar 2025Filed 12 JunMar 2026Filed 5 May
₹38.39₹35.51₹29.31₹35.73₹50.06₹54.97₹45.89₹64.82₹73.56₹84.53
As stated that year₹57.59₹53.26₹43.97₹53.60₹75.09₹82.45₹45.89₹64.82₹73.56₹84.53
₹38.39₹35.50₹29.31₹35.73₹50.06₹54.97₹45.89₹64.77₹73.53₹84.51
₹8.67–₹6.00₹8.67₹6.33₹6.33₹7.00₹51.00₹28.00₹28.00
––₹170.67₹197.56₹229.68₹253.49₹268.14₹282.34₹302.38₹361.16
Dividend payout22.6%–20.6%24.4%12.6%11.4%15.0%78.9%38.1%33.2%
Shareholder yield––––1.4%2.8%0.6%3.7%2.1%1.0%
Market cap at the year end (₹ crore)15,49412,2379,11211,92315,50615,66915,48828,09032,76435,046
Every year is restated for later splits and bonuses, so they do not break the line. The figure the company stated that year is under each line it differs from.

Ratios

Consolidated, years to March.Ajanta Pharma PE ratio and valuation

RatioMar 2017Mar 2018Mar 2019Filed 2 MayMar 2020Filed 21 MayMar 2021Filed 3 MayMar 2022Filed 11 MayMar 2023Filed 8 MayMar 2024Filed 3 MayMar 2025Filed 12 JunMar 2026Filed 5 May
Revenue growth15.9%6.5%−3.5%25.9%11.7%15.6%12.0%12.5%10.4%17.3%
Operating profit growth–−4.4%−14.0%20.6%46.1%−6.9%−15.7%49.6%7.5%10.7%
Net profit growth26.3%−7.5%−17.4%20.9%39.8%9.0%−17.5%38.8%12.8%14.7%
Earnings per share growth26.2%−7.5%−17.4%21.9%40.1%9.8%−16.5%41.3%13.5%14.9%
––17.1%19.3%23.4%22.8%17.7%23.5%25.0%25.4%
–––2.2 pts4.1 pts−0.6 pts−5.1 pts5.8 pts1.5 pts0.4 pts
From the net margin–––−0.5 pts4.9 pts−1.3 pts−6.0 pts4.2 pts0.5 pts−0.6 pts
From asset turnover–––2.1 pts−1.3 pts1.0 pts0.1 pts1.2 pts1.6 pts0.3 pts
From borrowing–––0.6 pts0.5 pts−0.3 pts0.8 pts0.5 pts−0.5 pts0.6 pts
Return on capital employed––21.7%22.2%29.4%24.6%19.2%29.0%29.4%25.8%
Cash conversion––––88.1%78.9%134.7%96.2%125.7%50.1%
Interest cover179.91,460.5426.249.3106.778.8111.7143.853.875.8
Debt to equity––0.020.020.000.000.000.000.000.05
Receivable days––821099311110310893124
Inventory days––415276434347283283308289
Payable days––214202212143147159155168
Cash conversion cycle, days––282184315315240233246246
Working capital days––1191141261408211996125
Asset turnover––0.760.860.810.850.860.900.960.98
Assets per rupee of net worth––1.201.241.271.251.311.341.311.34
Sales per rupee of plant––1.751.902.022.352.663.042.863.16
Capital spending to depreciation––––1.481.191.331.132.212.11
Plant being built, % of plant in use––22.3%9.7%7.6%10.7%14.9%18.5%10.8%14.9%
No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
18.9%
Cash from operations against operating profit
37.9%
Measure10 years5 years3 years
Revenue growth, yearly rate12.2%13.5%13.4%
Profit growth, yearly rate10.2%10.1%21.6%
Return on equity, average–22.9%24.6%
Return on capital employed, average–25.6%28.1%
Operating margin, average28.3%25.9%26.8%
Net margin, average20.2%19.1%19.5%
Asset turnover, average–0.910.95
Cash conversion cycle, days, average–256242
Interest cover, average268.792.891.1
Debt to equity, average–0.010.02

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations3,8252,471529
Cash from investing−1,374−740−429
Cash from financing−2,520−1,952−168
Capital spending1,159835365
Dividends paid1,5131,341350
Shares bought back1,0987420
Shares issued for cash000
Borrowings raised211211209
Borrowings repaid000

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9––––665776
Altman Z-scorePublished threshold 1.81––14.9912.9015.0414.969.8719.0419.3216.07
Beneish M-scorePublished threshold −1.78––––−2.42−1.98−2.79−2.14−2.78−1.75
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets––––10.145.748.15−0.742.8917.11
Cash from operations to profit, 3 yearsPublished threshold 0.7 times––––––0.991.011.180.89
Receivables growth less revenue growthOur threshold 0 percentage points–––42.83−16.4222.49−8.385.52−15.5839.43
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–––−57.2356.26−25.81−23.100.028.72−6.72
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–––−1.221.39−0.47−0.521.38−0.572.77
Assets under construction, years of additionsOur threshold 2 years of additions–––0.460.581.271.832.300.460.94
Effective tax ratePublished threshold 17.16 per cent21.8124.7224.7529.5627.3621.6421.1026.7322.6023.35
Tax charged less tax paid, % of profitOur threshold 10 percentage points–––––−4.650.80−1.29−4.56−2.71
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
14 Aug 2026CARE Ratings Limited (opens in a new tab)Fund-based/Non-fund-based-LT/STCARE AA+ / CARE A1+Review, Re-affirmStable62.50
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.